Literature DB >> 22622869

Chronic high-frequency stimulation therapy in hemiparkinsonian rhesus monkeys using an implanted human DBS system.

Yiqun Cao1, Peihao Yin, Xiaowu Hu, Yiqin Ge, Xiaoping Zhou.   

Abstract

Deep brain stimulation (DBS) is routinely used in the treatment of Parkinson's disease, tremor disease, dystonia, and epilepsy. This study aims to establish a hemiparkinsonian monkey model and to investigate the effect of implanted human DBS system for the chronic alleviation of parkinsonian symptoms. Hemiparkinsonism was induced in four rhesus monkeys by unilateral infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. DBS leads were implanted stereotaxically in the right subthalamic (STN) of the monkeys. Subcutaneous extension wires were used to connect the leads to the internal pulse generators (IPG) for stimulation in two of the monkeys (human DBS test group). Post-operative imaging studies confirmed optimal locations of lead contacts. One week later, the IPG was turned on to determine the optimal stimulating parameters, using apomorphine (APO)-induced rotation as a behavioral readout. Animal behavior was scored on a scale of 0-10 over a 12-month period using the modified disability rating scale of hemiparkinsonian monkeys (DRSH). Parkinsonian symptoms in the group of monkeys with DBS improved dramatically (DRSH 3-4) compared to controls (DRSH 7-8). DBS leads were within the STN without intracranial hemorrhage, infection, or other serious complications. Histological examination showed cell necrosis and lymphocytic infiltration of the tissues around the lead and STN gliosis surrounding the lead contact. This study demonstrates that therapeutically effective human DBS systems can be established in relevant disease models in monkeys. Such combination of human DBS systems in hemiparkinsonian monkeys should be valuable in studying the mechanism of action and chronic consequences of DBS therapy in humans.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22622869     DOI: 10.1007/s10072-012-1117-7

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  41 in total

1.  No tissue damage by chronic deep brain stimulation in Parkinson's disease.

Authors:  C Haberler; F Alesch; P R Mazal; P Pilz; K Jellinger; M M Pinter; J A Hainfellner; H Budka
Journal:  Ann Neurol       Date:  2000-09       Impact factor: 10.422

2.  Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson's disease.

Authors:  Alessandro Stefani; Andres M Lozano; Antonella Peppe; Paolo Stanzione; Salvatore Galati; Domenicantonio Tropepi; Mariangela Pierantozzi; Livia Brusa; Eugenio Scarnati; Paolo Mazzone
Journal:  Brain       Date:  2007-01-24       Impact factor: 13.501

Review 3.  Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease.

Authors:  Alim Louis Benabid; Stephan Chabardes; John Mitrofanis; Pierre Pollak
Journal:  Lancet Neurol       Date:  2009-01       Impact factor: 44.182

Review 4.  High-frequency stimulation of the subthalamic nucleus for the treatment of Parkinson's disease--a team perspective.

Authors:  Manjit K Sanghera; J Michael Desaloms; R Malcolm Stewart
Journal:  J Neurosci Nurs       Date:  2004-12       Impact factor: 1.230

5.  Deep brain stimulation of the subthalamic nucleus in Parkinson's disease.

Authors:  Robert Iansek; Jeffrey V Rosenfeld; Frances E Huxham
Journal:  Med J Aust       Date:  2002-08-05       Impact factor: 7.738

Review 6.  The treatment of movement disorders by deep brain stimulation.

Authors:  Hong Yu; Joseph S Neimat
Journal:  Neurotherapeutics       Date:  2008-01       Impact factor: 7.620

7.  Bilateral subthalamic stimulation in patients with Parkinson disease: long-term follow up.

Authors:  Rajesh Pahwa; Steven B Wilkinson; John Overman; Kelly E Lyons
Journal:  J Neurosurg       Date:  2003-07       Impact factor: 5.115

Review 8.  [Deep brain stimulation in the context of addiction--a literature-based systematic evaluation].

Authors:  R Bauer; S Pohl; J Klosterkötter; J Kuhn
Journal:  Fortschr Neurol Psychiatr       Date:  2008-07       Impact factor: 0.752

9.  Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

Authors:  K S Bankiewicz; E H Oldfield; C C Chiueh; J L Doppman; D M Jacobowitz; I J Kopin
Journal:  Life Sci       Date:  1986-07-07       Impact factor: 5.037

10.  Reversal of rigidity and improvement in motor performance by subthalamic high-frequency stimulation in MPTP-treated monkeys.

Authors:  A Benazzouz; C Gross; J Féger; T Boraud; B Bioulac
Journal:  Eur J Neurosci       Date:  1993-04-01       Impact factor: 3.386

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.